\"The numbers are fantastic,\" said Dr Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study. <\/p>\n
\"These are heavily treated patients who have no other options.\" <\/p>\n
The treatment, which has been dubbed 'a living drug' by doctors, works by filtering a patient's blood to remove key immune system cells called T-cells, which are then genetically engineered in the lab to recognise cancer cells. <\/p>\n
Cancer cells are very good a evading the immune system, but the new therapy essentially cuts the brakes, allowing immune cells to do their job properly. <\/p>\n
Martin Ledwick, Cancer Research UKs head cancer information nurse, said: These results are promising and suggest that one day CAR-T cells could become a treatment option for some patients with certain types of lymphoma. <\/p>\n
\"But, we need to know more about the side effects of the treatment and long term benefits. <\/p>\n
<\/p>\n
The rest is here:<\/p>\n
Terminal cancer patients in complete remission after one gene therapy treatment - Telegraph.co.uk<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" \"The numbers are fantastic,\" said Dr Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study. \"These are heavily treated patients who have no other options.\" The treatment, which has been dubbed 'a living drug' by doctors, works by filtering a patient's blood to remove key immune system cells called T-cells, which are then genetically engineered in the lab to recognise cancer cells. Cancer cells are very good a evading the immune system, but the new therapy essentially cuts the brakes, allowing immune cells to do their job properly. Continue reading